|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 413 NORTH LEE STREET |
Address2 | P.O. BOX 1417-DR49 |
City | ALEXANDRIA |
State | VA |
Zip Code | 22313 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 26672-12
|
||||||||
|
6. House ID# 302390000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: R. James Huber, Senior Vice President, Finance |
Date | 07/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R.1/S.350, the American Recovery and Reinvestment Act, related to health information technology and state Medicaid programs.
H.R. 1259, the Dextromethorphan Distribution Act, as related to the abuse of dextromethorphan.
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals.
S.726, Promoting Innovation and Access to Life-Saving Medicine Act, as related to the approval of generic biopharmaceuticals.
H.R.1450, Counterfeit Drug Prevention Act of 2009, as related to the prosecution of prohibited acts related to prescription drugs.
H.R.759, Food and Drug Administration Globalization Act of 2009, as related to the safety of prescription drugs.
H.R.1359/S.1292, Secure and Responsible Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs.
H.R.616/S.511, Access to Durable Medical Equipment Act, related to the exemption of pharmacies from Medicare accreditation requirements.
H.R.1970/S.956, Preserve Patient Access to Reputable DMEPOS Providers Act of 2009, as related to pharmacy exemption from the Medicare Part B surety bond requirement.
H.R.1191/S.1336, Safe Drug Disposal Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs.
H.R. 2552, Medical Waste Management Act of 2009, as related to the role of pharmacy in the disposal of prescription drugs.
H.R.3108, the Medication Therapy Management Benefits Act, related to expansion of the Medicare Part D medication therapy management benefit.
S.525/H.R.1298/S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009, as related to the importation of prescription drugs.
H.R.1548, Pathway for Biosimilars Act, as related to the approval of generic biopharmaceuticals.
S. 1383, Dextromethorphan Abuse Reduction Act of 2009, as related to the abuse of dextromethorphan.
H.R. 2923/S.256, Combat Methamphetamine Enhancement Act of 2009, as related to the abuse of methamphetamine.
The Fair Medicaid Drug Payment Act, as related to pharmacy reimbursement for generic drugs in the Medicaid program.
Various issues related to the role of pharmacy and pharmacists in healthcare reform, including pharmacy services in the Medicare program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Environmental Protection Agency (EPA), White House Office, Consumer Product Safety Commission (CPSC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Anderson |
|
|
|
Yong |
Choe |
|
|
|
Diane |
Darvey |
|
|
|
Kate |
Fry |
|
|
|
Carol |
Kelly |
|
|
|
Paul |
Kelly |
|
|
|
Julie |
Khani |
|
|
|
Kevin |
Nicholson |
|
|
|
Marc |
Schloss |
|
|
|
Heidi |
Ecker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
H.R. 1173, the Organized Retail Crime Act of 2008, as related to the prosecution of organized theft.
H.R. 1166, the E-Fencing Enforcement Act of 2008, as related to the prosecution of organized theft.
S. 470, Combating Organized Retail Crime Act of 2009, as related to the prosecution of organized theft.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Anderson |
|
|
|
Yong |
Choe |
|
|
|
Heidi |
Ecker |
|
|
|
Kate |
Fry |
|
|
|
Carol |
Kelly |
|
|
|
Paul |
Kelly |
|
|
|
Julie |
Khani |
|
|
|
Kevin |
Nicholson |
|
|
|
Marc |
Schloss |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
H.R.1409/S.560, the Employee Free Choice Act of 2009, as related to labor practices during organizing efforts.
Issues related to pension funding requirements and the Worker, Retiree, and Employer Recovery Act of 2008
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Anderson |
|
|
|
Yong |
Choe |
|
|
|
Heidi |
Ecker |
|
|
|
Kate |
Fry |
|
|
|
Carol |
Kelly |
|
|
|
Paul |
Kelly |
|
|
|
Julie |
Khani |
|
|
|
Marc |
Schloss |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R.2647/S.1390/S.1391, National Defense Authorization Act for Fiscal Year 2010, as related to pharmacy participation in the TRICARE program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steve |
Anderson |
|
|
|
Yong |
Choe |
|
|
|
Heidi |
Ecker |
|
|
|
Kate |
Fry |
|
|
|
Carol |
Kelly |
|
|
|
Paul |
Kelly |
|
|
|
Julie |
Khani |
|
|
|
Marc |
Schloss |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: List of membership available at www.nacds.org
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |